Enanta Pharmaceuticals, Inc.
NASDAQ:ENTABiotechnology
-$0.09 today
- Market cap
- $239.70M
- Beta
- 0.99
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$2.90
Volume 0.81M
Average 0.17M
ENTA Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Enanta Pharmaceuticals, Inc.NASDAQ: ENTA
Gross Profit · Q2 FY2026 · quarter ended Mar 2026
Gross profit grows in line with its trailing trend
Q2 FY2026 gross profit of $15.95M rose 6.9% year over year, ahead of the +5.5% change in trailing-twelve-month gross profit. Sequentially, it fell 14.3% from the prior quarter. Over 3 fiscal years it compounded at -11.0% a year.
Context
- Gross profit amounted to 93.0% of revenue in FY2025, down 7.0 pp from a year earlier.
- Gross profit increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +6.9% holds above the trailing-twelve-month pace of +5.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 60.74M USD
- Year-over-year change
- -10.2%
- 4-year CAGR
- -11.1%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 60.74M | -10.2% |
| FY2024 | 2024-09-30 | 67.64M | -14.6% |
| FY2023 | 2023-09-30 | 79.2M | -8.1% |
| FY2022 | 2022-09-30 | 86.16M | -11.2% |
| FY2021 | 2021-09-30 | 97.07M | — |
Gross Profit vs competitors
How ENTA compares with its peers on the latest reported figures
- ENTA's LTM Mar 2026 gross profit of $68M is the highest of the 11 companies compared; the peer median is $3.3M.
- Its year-over-year change of +5.5% is the 7th highest of 10, against a peer median of +46.9%.
- Gross profit amounts to 98.3% of revenue for ENTA, versus a peer median of 86.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $68M | +5.5% | -11.0% | 98.3% | |
| LTM Mar 2026 | $54.91M | +621.8% | — | 77.2% | |
| LTM Mar 2026 | $16.33M | +133.3% | — | 97.7% | |
| LTM Mar 2026 | $13.83M | — | — | 99.8% | |
| LTM Mar 2026 | $9.26M | +117.7% | -9.7% | 82.6% | |
| LTM Mar 2026 | $6.28M | -73.3% | +12.8% | 22.3% | |
| LTM Mar 2026 | $326K | +115.4% | — | 144.9% | |
| LTM Mar 2026 | -$793.21K | -354.2% | — | — | |
| LTM Mar 2026 | -$6.32M | +43.5% | — | — | |
| LTM Mar 2026 | -$31.63M | +46.9% | — | 86.7% | |
| LTM Mar 2026 | -$40.76M | -72.9% | — | — | |
| Peer median (excluding ENTA) | $3.3M | +46.9% | +1.5% | 86.7% | |
Competitors are the stored peer set for ENTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 97.07M | 86.16M | 79.2M | 67.64M | 65.32M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 4.59M |
| Gross Profit | 97.07M | 86.16M | 79.2M | 67.64M | 60.74M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 93.0% |
| Research & Development | 174.11M | 164.52M | 163.52M | 131.48M | 106.74M |
| Selling, General & Admin | 32.54M | 45.48M | 52.89M | 57.85M | 43.93M |
| Operating Expenses | 206.65M | 210M | 216.41M | 189.33M | 146.09M |
| Depreciation & Amortization | 3.33M | 2.97M | 2.37M | 2.34M | 5.09M |
| EBITDA | (104.25M) | (119.22M) | (123.48M) | (104.51M) | (70.78M) |
| EBITDA Margin | -107.4% | -138.4% | -155.9% | -154.5% | -108.4% |
| Operating Income | (109.57M) | (123.84M) | (137.21M) | (121.69M) | (85.35M) |
| Operating Margin | -112.9% | -143.7% | -173.2% | -179.9% | -130.7% |
| Interest Income | 2.02M | 1.57M | 11.36M | 14.77M | 9.48M |
| Interest Expense | 0 | 0 | 5.15M | 10.94M | 7.68M |
| Other Income / Expenses | 1.99M | 1.66M | 6.21M | 3.9M | 1.8M |
| Income Before Tax | (107.58M) | (122.19M) | (131M) | (117.79M) | (83.55M) |
| Pre-Tax Margin | -110.8% | -141.8% | -165.4% | -174.2% | -127.9% |
| Income Tax Expense | (28.58M) | (433K) | 2.82M | (1.74M) | (1.66M) |
| Net Income | (79M) | (121.76M) | (133.82M) | (116.05M) | (81.89M) |
| Net Margin | -81.4% | -141.3% | -169.0% | -171.6% | -125.4% |
| EPS (Basic) | (3.92) | (5.91) | (6.38) | (5.48) | (3.84) |
| EPS (Diluted) | (3.92) | (5.91) | (6.38) | (5.48) | (3.84) |
| Weighted Avg Shares | 20.17M | 20.6M | 20.97M | 21.16M | 21.34M |
| Weighted Avg Shares (Diluted) | 20.17M | 20.6M | 20.97M | 21.16M | 21.34M |
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
Intrinsic Alpha fair value
Locked
Current Price
$8.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.